OSPM-Enhanced AI Model to Identify Premalignant and Malignant Ocular Surface Tumors
March 23, 2025 updated by: Ningbo Eye Hospital
Prospective Evaluation of an OSPM-Enhanced Deep Learning Model for Identifying Premalignant and Malignant Ocular Surface Tumors
An OSPM-enhanced deep learning model has been developed for identifying premalignant and malignant tumors using data retrospectively collected from the Ningbo Eye Hospital, Jiangdong Eye Hospital, and the Eye Hospital of Wenzhou Medical University.
To further substantiate the model's effectiveness, we intend to evaluate it prospectively at Ningbo Eye Hospital.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zhejiang
-
Ningbo, Zhejiang, China, 315040
- Ningbo Eye Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Child, Adult, Older Adult
Description
Inclusion Criteria:
● Ocular surface tumor images with histopathological findings
Exclusion Criteria:
● Low-quality images
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AUROC
Time Frame: 3 months
|
area under the receiver operating characteristic curve
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2024
Primary Completion (Actual)
October 1, 2024
Study Completion (Actual)
November 1, 2024
Study Registration Dates
First Submitted
August 20, 2024
First Submitted That Met QC Criteria
August 20, 2024
First Posted (Actual)
August 22, 2024
Study Record Updates
Last Update Posted (Actual)
March 26, 2025
Last Update Submitted That Met QC Criteria
March 23, 2025
Last Verified
March 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NEH202408
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.